Similarly, an acute, double-blinded, randomized, placebo-controlled, crossover study of a rapid-acting insulin analog (glulisine) has also shown diminished therapeutic response of IN-insulin in APOE ε4 carrier AD patients [72]. This evidence concerns the gene APOE and Alzheimer disease.